Paclitaxel , Analysis of standard products, ≥99% , 33069-62-4
Synonym(s):
Baccatin III N-benzyl-β-phenylisoserine Ester, TAXOL;O-De[(2R,3S)-3-(Benzoylamino)-2-hydroxy-3-phenylpropanoyl]paclitaxel;Paclitaxel;TAXOL InSolution, Baccatin III N-benzyl-β-phenylisoserine Ester
CAS NO.：33069-62-4
Empirical Formula: C47H51NO14
Molecular Weight: 853.92
MDL number: MFCD00869953
EINECS: 608-826-9
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB359.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 213 °C (dec.)(lit.) |
| Boiling point: | 774.66°C (rough estimate) |
| alpha | D20 -49° (methanol) |
| Density | 0.200 |
| refractive index | -49 ° (C=1, MeOH) |
| Flash point: | 9℃ |
| storage temp. | 2-8°C |
| solubility | methanol: 50 mg/mL, clear, colorless |
| form | powder |
| pka | 11.90±0.20(Predicted) |
| color | white |
| Water Solubility | 0.3mg/L(37 ºC) |
| λmax | 227nm(MeOH)(lit.) |
| Merck | 14,6982 |
| BRN | 1420457 |
| Stability: | Stable. Incompatible with strong oxidizing agents. Combustible. |
| InChIKey | RCINICONZNJXQF-MZXODVADSA-N |
| LogP | 3.950 (est) |
| CAS DataBase Reference | 33069-62-4(CAS DataBase Reference) |
| EPA Substance Registry System | Paclitaxel (33069-62-4) |
Description and Uses
Paclitaxel, a natural product isolated from the bark of the Pacific yew, is effective in treating refractory metastatic ovarian cancer. Unlike any other antineoplastic agents, paclitaxel appears to have several possible mechanisms of action, including an antimicrotubule action through the promotion of tubulin polymerization and stabilization of microtubules, thereby, halting mitosis and promoting cell death. The supply of paclitaxel is limited by its low natural abundance and currently it is being manufactured by a semi-synthetic route from deacetylbaccatin Ⅲ that is isolated from the needles of the yew tree. Recent completion of two total syntheses of taxol conquered the structural complexity of the title compound and may be useful in obtaining certain closely related analogs, some of which have been found to have antitumor activity. Paclitaxel has potential uses in the treatment of metastatic breast cancer, lung cancer, head and neck cancer, and malignant melanoma.
Paclitaxel is an antineoplastic that used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanc ed forms of Kaposi's sarcoma. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It is also used in the study of structure and function of microtubles into tubulin.
Safety
| Symbol(GHS) |    GHS05,GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H315-H317-H318-H334-H335-H340-H360D-H372 |
| Precautionary statements | P202-P260-P280-P302+P352-P305+P351+P338-P308+P313 |
| Hazard Codes | Xn |
| Risk Statements | 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22 |
| Safety Statements | 22-26-36/37/39-45 |
| RIDADR | 1544 |
| WGK Germany | 3 |
| RTECS | DA8340700 |
| F | 10-21 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29329990 |
| Hazardous Substances Data | 33069-62-4(Hazardous Substances Data) |
| Toxicity | LD50 intraperitoneal in mouse: 128mg/kg |
